<DOC>
	<DOCNO>NCT01239511</DOCNO>
	<brief_summary>The objective study evaluate dose-response three different dose level STA-2 ( 900 mg daily , 1800 mg daily 2700 mg daily 42 day ) versus placebo patient chronic stable angina .</brief_summary>
	<brief_title>Phase IIb Study STA-2 Patients With Chronic Stable Angina</brief_title>
	<detailed_description>The objective study evaluate dose-response three different dose level STA-2 ( 900 mg daily , 1800 mg daily 2700 mg daily 42 day ) versus placebo patient chronic stable angina . Treatment Group A : 150 mg STA-2 , 2 capsule t.i.d. , meal ( 900 mg STA-2 total dose per day ) Treatment Group B : 300 mg STA-2 , 2 capsule t.i.d. , meal ( 1800 mg STA-2 total dose per day ) Treatment Group C : 450 mg STA-2 , 2 capsule t.i.d. , meal ( 2700 mg STA-2 total dose per day ) Placebo Group : Placebo capsule , 2 capsule t.i.d. , meal</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<criteria>1 . Male female age â‰§ 20 year ; 2 . Subjects weight &gt; 50 kg 3. subject 50 % coronary stenosis document catheterization ever receive coronary intervention ; 4 . The two ETT result screen ( Visit 1 ) baseline ( Visit 2 ) show great equal 1 mm STsegment depression within exercise duration ; 5 . The difference exercise duration screening ( Visit 1 ) baseline ( Visit 2 ) exceed 20 % long test ; 6 . Able provide write informed consent . 1 . Subjects pacemaker rhythm , unstable angina myocardial infarction within precede 3 month ; 2 . Subjects heart failure ( New York Heart Association class III IV ) , uncorrected valvular congenital heart disease , subject need digoxin digitalis ; 3 . Subjects rest EKG abnormality prevent interpretation ischemia judge investigator ; 4 . Subjects COPD require bronchodilator ; 5 . Subjects impaired hepatic function ( define AST ALT &gt; 2X upper limit normal value ) , impaired renal function ( define serum creatinine &gt; 1.5 mg/dL ) , diagnosis chronic renal/hepatic disease ; 6 . Subjects document evidence gastroduodenal ulcer disease , gastrointestinal bleeding gastrointestinal disease within precede 3 month judge investigator ; 7 . Subjects history evidence medical condition would expose undue risk significant adverse event interfere safety assessment course trial , include limited hepatic , renal , respiratory , cardiovascular , endocrine , immune , neurological , hematological disease determine clinical judgment investigator ; 8 . Subject condition could interfere performance exercise tolerance test judge investigator ( e.g. , knee/ankle arthropathy , Parkinsonism , stoke ) ; 9 . Female subject childbearing potential : lactating ; positive pregnancy test ( urine ) V1 ; 10 . Subject receive investigational agent within 28 day prior first dose investigational product ; 11 . Subjects administer STA2 prior clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>